|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Furthermore, CCNY mRNA expression positively correlated with histologic types (squamous cell carcinoma vs. adenocarcinomas; P = .048) and with the tumor size (size > 3 cm vs. size ≤ 3 cm; P = .010) in NSCLC.
|
21273179 |
2011 |
|
Adenocarcinoma, Clear Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
We also found three additional fusion transcripts involving genes belonging to the cyclin family: ANXA5-CCNA2 and PDE4D-CCNB1 were detected in two endometrioid carcinomas, whereas CCNY-NRG4 was identified in a clear cell carcinoma.
|
29633253 |
2018 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Cell cycle protein cyclin Y is associated with human non-small-cell lung cancer proliferation and tumorigenesis.
|
21273179 |
2011 |
|
Carcinoma of lung
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The expression status of CCNY in lung cancer and its clinical significance remain unknown.
|
20596919 |
2010 |
|
Carcinoma of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
Serum anti-CCNY autoantibody is an independent prognosis indicator for postoperative patients with early-stage nonsmall-cell lung carcinoma.
|
24167380 |
2013 |
|
Carcinoma of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
Hence, the aim of this study was to explore the potential role of CCNY in lung cancer.
|
21273179 |
2011 |
|
Carcinoma of lung
|
0.040 |
Biomarker
|
disease |
BEFREE |
CCNY, a novel cyclin family member, plays an increasingly important role in the progression of tumor invasion and metastasis, including lung cancer.
|
30774378 |
2019 |
|
Crohn Disease
|
0.430 |
GeneticVariation
|
disease |
BEFREE |
Colon-only CD (n = 228) was compared with healthy controls: three of six UC SNPs (in MST1, HLA-DRA, and IL-23R) and 11 of 34 CD SNPs: in IRGM, NOD2 (rs2066845), CCNY, MST1, IL23R, PTPN22, C11orf30, ZNF365, PTPN2, PSMG1, and rs1456893 were significantly associated.
|
21830272 |
2011 |
|
Crohn Disease
|
0.430 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease.
|
18587394 |
2008 |
|
Crohn Disease
|
0.430 |
GeneticVariation
|
disease |
LHGDN |
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis.
|
18438405 |
2008 |
|
Crohn Disease
|
0.430 |
GeneticVariation
|
disease |
BEFREE |
We identified multiple previously unreported or unconfirmed disease associations, including known CD loci (ICOSLG and TNFSF15) and T1D loci (TNFAIP3) that confer UC risk, known UC loci (HERC2 and IL26) that confer T1D risk and known UC loci (IL10 and CCNY) that confer CD risk.
|
20176734 |
2010 |
|
Crohn Disease
|
0.430 |
Biomarker
|
disease |
CTD_human |
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis.
|
18438405 |
2008 |
|
Crohn's disease of large bowel
|
0.300 |
Biomarker
|
disease |
CTD_human |
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis.
|
18438405 |
2008 |
|
Crohn's disease of the ileum
|
0.300 |
Biomarker
|
disease |
CTD_human |
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis.
|
18438405 |
2008 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We identified multiple previously unreported or unconfirmed disease associations, including known CD loci (ICOSLG and TNFSF15) and T1D loci (TNFAIP3) that confer UC risk, known UC loci (HERC2 and IL26) that confer T1D risk and known UC loci (IL10 and CCNY) that confer CD risk.
|
20176734 |
2010 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data suggest that CCNY might play an important role in glioma tumorigenisis.
|
20441050 |
2010 |
|
IIeocolitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis.
|
18438405 |
2008 |
|
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RESULTS Expression of CCNY in human HCC tumor tissues was significantly increased when compared with adjacent normal liver (all P<0.05).
|
29557391 |
2018 |
|
Malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
Hence, the aim of this study was to explore the potential role of CCNY in lung cancer.
|
21273179 |
2011 |
|
Malignant neoplasm of lung
|
0.030 |
Biomarker
|
disease |
BEFREE |
CCNY, a novel cyclin family member, plays an increasingly important role in the progression of tumor invasion and metastasis, including lung cancer.
|
30774378 |
2019 |
|
Malignant neoplasm of lung
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The expression status of CCNY in lung cancer and its clinical significance remain unknown.
|
20596919 |
2010 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
The CFP1 and 14-3-3 genes can be used as prognostic markers in patients with GC, but the study is still needed to confirm.
|
31496919 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
We identified several candidates implicating the CDK16/CCNY complex in cytoskeletal dynamics, and we focused on the microtubule-associated protein regulator of cytokinesis (PRC1), an essential protein for cell division that organizes antiparallel microtubules and whose deregulation may drive genomic instability in cancer.
|
30992425 |
2019 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Overexpression of cyclin Y in non-small cell lung cancer is associated with cancer cell proliferation.
|
20596919 |
2010 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
CCNY mRNA expression associated with histologic types of NSCLC and promoted the malignant growth of lung cancer cell line in vivo and in vitro.
|
21273179 |
2011 |